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Abstract 
OBJECTIVES:  The aim of this report was to assess the clinical effectiveness of two 
Gene expression profiling (GEP) and two expanded immunohistochemistry (IHC) 
tests compared with current prognostic tools in guiding the use of adjuvant 
chemotherapy in patients with early breast cancer.   
METHODS:  A systematic review of the evidence on clinical effectiveness of 
OncotypeDX, IHC4, MammaPrint and Mammostrat, compared with current clinical 
practice using clinicopathological parameters, in women with early breast cancer 
was conducted.  Ten databases were searched to include citations to May 2016. 
RESULTS:  Searches identified 7064 citations, of which 41 citations satisfied the 
criteria for the review. A narrative synthesis was performed. Evidence for 
OncotypeDX demonstrated the impact of the test on decision-making and there was 
some support for OncotypeDX predicting chemotherapy benefit.  There were 
relatively lower levels of evidence for the other three tests included in the analysis.  
MammaPrint, Mammostrat and IHC4 tests were limited to a small number of studies.   
Limitations in relation to study design were identified for all tests.  
CONCLUSIONS:  The evidence base for OncotypeDX is considered to be the most 
robust.  Methodological weaknesses relating to heterogeneity of patient cohorts and 
issues arising from the retrospective nature of the evidence were identified.  Further 
evidence is required for all of the tests using prospective randomised controlled trial 
data. 
Keywords: Gene expression profiling; Immunohistochemistry; breast cancer. 
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Introduction 
Breast cancer is not a single disease but rather a group of heterogeneous tumours at 
the molecular level(1).  Based on the knowledge that certain biological features of 
cancers may indicate an increased likelihood of rapid growth and metastasis (in 
particular, distant recurrence) gene expression profiling (GEP) and expanded 
immunohistochemistry (IHC) (or protein expression) tests have been developed.  
These tests have an aim of improving the targeting of chemotherapy in breast cancer 
by stratifying patients and identifying those patients who will gain most benefit from 
adjuvant chemotherapy.  These tests either measure the risk of cancer recurrence 
(by incorporating a wider range of biomarkers with prognostic significance than 
standard clinico-pathological algorithms), or aim to identify breast cancer sub-types 
which may influence recurrence risk and guide treatment decisions.   
In current practice treatment regimens are tailored according to traditional clinical 
FKDUDFWHULVWLFVVXFKDVDJHWXPRXUVL]HDQGJUDGHWRJHWKHUZLWKDWXPRXU¶V
molecular signature based on estrogen (ER) and progesterone (PR) receptor status 
and HER2 receptor status(2), although guidelines may differ slightly from country to 
country.  
The purpose of this systematic review was to evaluate the clinical effectiveness of 
GEP and expanded IHC tests in guiding the use of adjuvant chemotherapy in women 
with early breast cancer. A summary of the evaluated gene expression profiling and 
expanded immunohistochemistry tests is presented in Table 1. This review was 
originally undertaken to inform the UK National Institute for Health and Care 
Excellence's (NICE) assessment of GEP (MammaPrint, OncotypeDX) and IHC 
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(IHC4 and Mammostrat) tests to guide selection of chemotherapy regimens in breast 
cancer management(3), but has been updated with new evidence up to May 2016.   
Table 1 here 
Method 
A systematic review of the evidence was undertaken according to the general 
principles recommended in the Centre for Reviews and Dissemination (CRD)(4) 
guidance for undertaking systematic reviews, and reported according to the 
Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 
statement(5), and The NICE Diagnostic Assessment Programme Interim Methods 
Statement(6).   
 
Data sources and searches 
Ten electronic databases were searched, these were: Medline and Medline in 
Process via Ovid SP, Embase via Ovid SP; Cochrane Library databases all via 
Wiley: Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane 
Database of Systematic Reviews (CDSR),  Database of Abstracts of Reviews of 
Effects (DARE) ,  Health Technology Assessment Database (HTA), NHS Economic 
Evaluation Database(NHS-EED);  Web of Science databases all via Thomson 
Reuters: BIOSIS Previews, Science Citation Index Expanded (SCI-Expanded) and 
the Conference Proceedings Citation Index- Science (CPCI-S).  
The search strategy used free text and thesaurus terms and combined breast cancer 
related synonyms (e.g. breast neoplasm) with terms related to gene expression 
SURILOLQJ WHVWVRUELRPDUNHUV HJ0DPPD3ULQWRU ³JHQH"WZHQW\RQH´$SXEOLFDWLRQ
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date limit of January 2002 was applied.  This was the date that the longest standing 
test used in the review had been devised, as confirmed by manufacturers¶ 
submissions to NICE as part of the original review, and therefore it would not be 
possible for evidence to predate this. For the OncotypeDX and MammaPrint test, the 
current review used two previous systematic reviews(7,8) to identify included 
studies, thus the searches were limited from January 2009 (last date from earlier 
reviews) for these tests. Although a number of other systematic reviews examining 
GEP tests have been reported, these reviews(7,8) were considered the most 
appropriate reviews to update.  The reviews were assessed as being of high quality, 
and in particular the search strategies were assessed as being complete. No other 
limits were applied to the searches. An update search was conducted in Medline and 
Medline in Process from January 2013 - May 2016. 
 Supplementary search techniques were also undertaken to augment the topic 
searches, these included hand searching of relevant journals, citation searches of 
included papers in the review, searching of conference proceedings, and finally 
experts in the field were contacted to ask for suggestions for relevant evidence for 
the project. 
Study selection 
The inclusion of potentially relevant articles was undertaken using a two-stage 
process.  First, all titles and abstracts were screened for inclusion, followed by the 
assessment of full manuscripts.  Both stages were undertaken by one reviewer and 
any uncertainties in the selection process were resolved through discussion with 
another reviewer.  All study designs were included. Eligible studies included adult 
patients diagnosed with early invasive breast cancer.  The index test included 
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OncotypeDX, MammaPrint, IHC4 or Mammostrat.  The comparator was standard 
care and could include the use of Adjuvant! Online (AoL) and/or the Nottingham 
Prognostic Index (NPI), to predict the risk of recurrence and survival for patients with 
early breast cancer.  The outcome measure was FOLQLFDO XWLOLW\ WKH WHVW¶V DELOLW\ WR
discriminate between those who will have more or less benefit from a therapeutic 
intervention) (7,8).  Specifically, (i) the ability of the test to predict treatment effect 
with adjuvant chemotherapy, and (ii) to what extent are test results used in treatment 
decisions.  Studies published in languages other than English (unless no other 
comparable data existed) were excluded.  Abstracts were considered but only 
included if they represented significant new knowledge, such as prospective RCT 
evidence. 
 
Data extraction and quality assessment 
Data relating to study design, methodological quality, and outcomes, were extracted 
by one reviewer into a standardised data extraction form and independently checked 
for accuracy by a second.   Discrepancies were resolved by discussion.  The 
methodological quality of each included study was assessed by two reviewers 
according to the criteria recommended by Altman (2001)(9) for assessing the internal 
validity of prognostic (predictive factor) studies.   
 
Data synthesis and analysis  
Although a meta-analysis was planned, this was not considered appropriate due to a 
high degree of heterogeneity e.g. study populations, outcomes and diagnostic 
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thresholds between and within studies.  Therefore, data were tabulated and 
discussed in a narrative review.  
 
Results 
PRISMA flow 
Figure 1 summarises the process of identifying and selecting relevant literature.  Of 
the 7064 citations identified, 29 new studies (30 citations) were identified and were 
added to the 11 studies from the previous systematic reviews. 
Figure 1 about here 
Study and patient characteristics 
Forty studies (41 citations) were included in the review.  All studies were published 
between 2002 and May 2016.    
Most of the evidence was related to the OncotypeDX (32 studies).  Four studies 
related to the prediction of treatment effect with adjuvant chemotherapy, with the 
remaining 28 studies relating to evidence on the test result leading to changes in 
treatment decisions.  Six studies were identified for MammaPrint, all relating to 
evidence on the test result leading to changes in treatment decisions.  Only one 
relevant study was identified for IHC4, and one for Mammostrat.  The IHC4 study 
provided evidence relating to the test leading to changes in treatment decisions, 
whereas the Mammostrat study provided evidence on the prediction of treatment 
effect with adjuvant chemotherapy.  Details of the study and patient characteristics, 
together with key findings of the included studies are provided in Tables 2 and 3. 
 
9 
 
Quality Assessment 
Limitations in the clinical data were identified for all tests.  No studies had a 
prospective, randomised controlled trial (RCT) design and only five studies included 
a prospective analysis of archived tissue samples from a previous RCT 
(OncotypeDX n=4; Mammostrat n=1).  For the four OncotypeDX studies and the one 
Mammostrat study providing evidence relating to the prediction of treatment effect 
with adjuvant chemotherapy, the overall risk of bias was judged to be moderate, 
although retrospective analysis of archived tissue samples, the evidence was 
derived from relatively large scale RCTs.  The remaining 28 OncotypeDX studies 
providing evidence relating to changes in treatment recommendations, were in the 
main, small scale studies (n=25-979).  Fifteen were retrospective in study design, 
and some (n=14) did not provide full details of the patient characteristics.  Similarly, 
of the six studies identified for MammaPrint two were retrospective in study design, 
and some were lacking full details of patient characteristics.  The IHC4 study was 
prospective in design, however the sample size was relatively small (n=124).  
Overall, particularly for the studies relating to evidence of the tests leading to 
changes in treatment decisions, there was a high level of clinical heterogeneity 
across studies both within each test and across the four tests.   
Table 2 here 
Table 3 here 
Narrative data synthesis 
Prediction of treatment effect with adjuvant chemotherapy 
OncotypeDX 
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Studies by Paik, Tang and Shak et al.(10), Albain, Barlow and Shak et al.(11), Tang, 
Shak and Paik et al.(12) and Tang, Constantino and Crager et al.(13) assessed the 
predictive ability of OncotypeDX using archived tissue samples collected during 
randomised controlled trials comparing tamoxifen with tamoxifen plus chemotherapy.  
The strongest evidence appeared to be presented by Paik, Tang and Shak et al.(10).  
The OncotypeDX recurrence score was found to be correlated with chemotherapy 
benefit, defined in terms of 10-year DRFS, with a significantly increased benefit from 
the use of chemotherapy in the OncotypeDX high-risk group compared with the low-
risk group, in ER+, LN- breast cancer patients.  However, in a multivariate analysis 
the benefit from chemotherapy was unclear due to large confidence intervals in the 
low and intermediate RS risk groups.  Albain, Barlow and Shak et al.(11) 
demonstrated that the RS was prognostic for tamoxifen-treated patients with positive 
nodes and predicts significant benefit of chemotherapy in tumours with a high 
recurrence score.  They concluded that a low score could identify women who might 
not benefit from anthracycline-based chemotherapy, despite positive nodes.   
It was also reported by Tang, Shak and Paik et al.(12) that both RS and AoL 
provided strong independent prognostic information in tamoxifen treated patients, 
and that RS used alone remained the best predictor of chemotherapy benefit in ER+, 
LN- breast cancer(13).   
 
Of these four studies reporting evidence that OncotypeDX predicts benefit from 
chemotherapy, only one, on a LN+ population(11) presented that had not come from 
the NSABP cohorts.  However, there were limitations associated with this study.  It 
had only a moderate sample size, and the time over which tumour samples were 
collected was not reported, therefore they may be differences in diagnostic criteria 
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being applied. Two other studies(12,13) reported the same trial data as Paik, Tang 
and Shak et al.(10) from the NSABP cohorts, introducing biases associated with 
double counting in the evidence base as a whole.  It should further be noted that the 
Paik, Tang and Shak et al.(10) study may also have been subject to bias, as some 
patients in the validation dataset were also in the training dataset which may partly 
explain the treatment interaction seen with OncotypeDX.    
Mammostrat 
No prospective studies of the impact of Mammostrat on long-term outcomes such as 
overall survival were identified. Initial evidence for the predictive ability of 
Mammostrat from one study(14) suggests that low and high-risk groups benefited 
from chemotherapy, with high-risk patients benefiting more than low- risk. The 
intermediate-risk group did not appear to benefit.   
 
Changes in treatment recommendations as a result of testing 
OncotypeDX 
Twenty-eight studies (see table 3) provided evidence on the impact of OncotypeDX 
on clinical decision-making.  These studies indicated that the use of OncotypeDX 
leads to changes in treatment recommendations for between 21% and 74% of all 
patients who underwent OncotypeDX testing.  Three studies (17,24,25) did not 
report whether changes led to increased or decreased use of chemotherapy.  
However, where this was reported the number of patients being recommended 
chemotherapy after the test was introduced declined in most studies.  This change 
from chemotherapy to no chemotherapy ranged from 6% to 51.4% of all patients 
tested.  However, in one study more chemotherapy was used after the introduction 
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of OncotypeDX(28).  It was not clear in a large number of the studies whether these 
figures represented actual changes in the treatments patients received.  
MammaPrint 
Six studies were identified which provided evidence on changes in treatment 
recommendations as a result of MammaPrint (see table 3).  These studies indicated 
that the use of MammaPrint in addition to clinicopathological factors led to changes 
in treatment recommendations for between 18% and 40% of all patients tested, and 
that the between 2% and 32% of all patients would be recommended to change from 
chemotherapy to no chemotherapy.  One of these studies(45) reported the use of 
MammaPrint compared to AoL would result in altered treatment advice for 40% of 
patients.  However, this was based on the assumption that all patients classified as 
high-risk would receive chemotherapy and patients classified as low risk would not 
receive chemotherapy.  Again, in a number of these studies it is not clear if actual 
treatment changes occurred following introduction of the test. 
A prospective observational study(43) showed that adjuvant treatment was 
recommended for 48% of patients based on, and Dutch Institute for Healthcare 
Improvement (CBO) guidelines (2004) alone, increasing to 62% when MammaPrint 
was added.  This increased the number of patients receiving adjuvant systemic 
therapy by 20 (5%).  For the other guidelines assessed (St Gallen guidelines, the 
NPI and AoL), less adjuvant chemotherapy would be given when the data was based 
on prognostic signature alone are used.   A 5 year follow up study (44) showed that 
15% of the MammaPrint low risk patients received adjuvant chemotherapy versus 
81% of the high-risk patients.  The 5 year distant recurrence free interval (DRFI) 
probabilities for MammaPrint low-risk patients were 97%, and 91.7% for the high-risk 
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patients. Actual treatment decisions were based on restrictive CBO guidelines, and 
doctors and patients preferences limiting the generalisability of these findings. 
IHC4 
Evidence from one prospective study (50) demonstrated that the IHC4 test led to 
changes in treatment recommendations for 34% of the patients, with 25% 
recommended to switch from chemotherapy to no chemotherapy.  As there is only 
one study available and it has a small sample size (n=124), it is difficult to make 
generalisations based on this evidence.  Again, it is not clear whether actual 
treatment given was changed. 
 
Discussion 
OncotypeDX currently has the largest body of evidence on clinical utility relative to 
the other three tests included in this review.  Although, no prospective studies 
reporting the impact of OncotypeDX on long term outcomes, such as overall survival, 
yet exist.   The Paik, Tang and Shak et al.(10) study represented the most robust 
evidence of clinical utility.  The study showed a decreased relative benefit of 
chemotherapy in the lower-risk groups. However, the specific cancers in the low-risk 
groups were less likely to respond to chemotherapy, independent of actual survival 
probability.  Other specific limitations include that fact that in one study (32), 
compared to the study regimens, more effective chemotherapy regimens are 
currently being used, and more than 44% of patients were aged below 50 years old, 
limiting the generalisability of the findings.  
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The evidence base for MammaPrint, is primarily based on small sample sizes 
(n<427).  Some studies were retrospective in design and had heterogeneous patient 
populations.   Some studies included only pre-menopausal women, which may 
overestimate the benefit of MammaPrint in the early breast cancer population as a 
whole, given that younger women are likely to be at higher risk of recurrence and are 
more likely to be classified as poor prognosis using MammaPrint.  Further evidence 
is required to clarify whether using the test will improve the use of adjuvant 
chemotherapy in the management of breast cancer.  It is also unclear to what extent 
MammaPrint risk groups are predictive of chemotherapy benefit or how the use of 
MammaPrint will improve patient outcomes through increases in disease-free and 
overall survival.   
One study on Mammostrat(14) provides evidence relating to the benefit of 
chemotherapy by risk group. However, this indicates that both low and high-risk 
groups benefit, whilst it is unclear how those in the moderate risk group would be 
affected.  Further evidence is required.  In particular there was no published 
evidence on the impact of the test on decision-making.  
One clinical utility study was available for IHC4(50).  This study provided evidence 
on the impact of the test on decision-making leading to reductions in the amount of 
chemotherapy recommended.  Although the design was prospective it included a 
relatively small sample of patients. 
Limitations 
The varied nature of the evidence base makes comparisons between tests difficult.  
A characteristic feature of the studies across all tests was their heterogeneity, and a 
large proportion of the studies were small.  Many studies used old archived tumour 
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samples, and some, retrospective chart review to elicit treatment recommendations 
before and after testing.  There was a lack of standardised decision-making tools 
both within and between studies and non-standardised methods of patient selection 
were used.  Furthermore, a number of the studies for OncotypeDX and MammaPrint 
were funded by the manufacturer giving rise to potential issues of conflict of interests 
and publication bias.  
Conclusion and Implications 
One of the tests (OncotypeDX) has a reasonably large evidence base, although 
there are some methodological weaknesses relating to this evidence, in terms of 
heterogeneity of patient cohorts, and retrospective study design. The previous 
systematic reviews(7,8) on which our updates were based reported that OncotypeDX 
was furthest along the validation pathway, and that recurrence score was 
significantly correlated with disease-free-survival and overall survival. There was 
also some evidence that there may be a significant benefit from the use of 
chemotherapy in the OncotypeDX high-risk group, although it was acknowledged 
that this study may have been subject to bias. Our previous review (3) and this 
update demonstrates that further larger studies have now reported, which support 
the prognostic capability of the OncotypeDX test, and in the evidence base has been 
extended to include the LN+ population.  Also, further studies have presented 
evidence on the impact of OncotypeDX on clinical decision-making.  The previous 
reviews(7,8) indicated that evidence relating to the clinical validity of MammaPrint 
was not always conclusive or supportive of the prognostic value of the test, and one 
study was identified which suggested that MammaPrint had an impact on clinical 
decision-making.  Our previous review (3), together with this update identified 
studies which showed the MammaPrint score is a strong independent prognostic 
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factor and may provide additional value to standard clinicopathological measures, 
although the populations in all of these studies were relatively small. Further studies 
on the clinical utility of MammaPrint reported on test reclassification against currently 
used guidelines, reporting that treatment advice for a percentage of patients may 
change. However, none of the studies provided evidence of actual changes in 
treatment decisions following introduction of the test. 
This update has demonstrated that in comparison to our original review(3) a number 
of new studies have emerged which assess the effect of the tests on clinical decision 
making.  However, most of these studies are small scale and it remains the case that 
further robust evidence on the clinical utility of all of these tests is needed.  This 
would include studies investigating predictive ability, and prospective studies 
investigating how the tests will be used in clinical practice.  Two ongoing trials 
relating to OncotypeDX(51) and MammaPrint(52) have been designed to address 
some of these issues, specifically relating to the effect of these tests on patient 
outcomes and their ability to predict treatment response.  The TAILORx trial(51) 
aims to demonstrate that endocrine treatment alone is non-inferior to 
chemoendocrine treatment in women with an intermediate OncotypeDX score. 
Patients allocated to an intermediate risk group using the recurrence score will 
receive endocrine therapy and be randomly assigned to chemotherapy or no 
chemotherapy. The MINDACT trial(52) aims to assess the value of MammaPrint in 
predicting which patients would benefit from chemotherapy compared with Adjuvant! 
Online.  Patients assessed as high risk by one method and low risk by the other will 
then be randomised to follow the treatment indicated by MammaPrint or the 
treatment indicated by Adjuvant! Online. Two further objectives of the trial relating to 
the efficacy of different chemotherapy agents and endocrine treatment strategies are 
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addressed by two further stages of randomisation. These trials will result in direct 
evidence that these tests in breast cancer patients lead to improvement in outcomes 
with the use of RCTs comparing the outcomes of patients following standard 
management to those of patients managed with the aid of the expression-based 
assays.   All tests would benefit from further evidence demonstrating how they will be 
used in the current decision-making process and, especially, how this will impact on 
patient management decisions. 
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Table 1:  Summary of evaluated gene expression profiling and expanded 
immunohistochemistry tests. 
  OncotypeDX MammaPrint IHC4 Mammostrat 
Function Risk of recurrence   Risk of recurrence Risk of recurrence  Subtyping and 
Risk of 
recurrence 
Technology Reverse 
transcription 
polymerase chain 
reaction  
Microarray Combining 4 IHC 
tests & clinical 
parameters to 
derive prognostic 
score 
Uses 5 
biomarkers to 
derive risk score 
(21 gene)  (70 gene)     
Location of 
testing 
Central  Central Irvine, USA Local (but quality 
assurance issues 
need to be  
addressed) 
Central  
Type of 
sample 
Formulin fixed 
paraffin embedded 
Fresh 
(Use of Formulin 
fixed paraffin 
embedded has now 
been introduced)  
Formulin fixed 
paraffin embedded 
Formulin fixed 
paraffin 
embedded 
Population ER +, LN-, LN 1-3 ER+ (or ER-), LN-, 
LN 1-3, tumour size 
<5cm 
Post menopausal. 
ER+, LN- 
ER+, LN-, LN 1-3  
Presentation 
of results 
RS and risk group 
(Low  <18, 
Intermediate 18-
30, high>=31) 
2 categories ± low 
and  high risk  
IHC4 risk score  Risk groups - 
(High. >0.7, 
Moderate, 
/RZ 
Cost GBP 2,580 (EUR  
3263) 
GBP 2,675 (EUR 
3387) 
Approx GBP 100- 
200 (EUR 126-253)  
Approx GBP 
1120-1620 (EUR 
1417-2049) 
RS = recurrence score, ROR = risk of recurrence score, ER+ = oestrogen receptor positive, ER- = 
oestrogen receptor negative, LN- = lymph node negative, LN 1-3 = 1-3 lymph nodes involved, IHC = 
Immunohistochemistry. 
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 Table 2:  Summary of patient characteristics, study characteristics, and key 
findings relating to the prediction of treatment effect with adjuvant 
chemotherapy 
Autho
r 
(year) 
Design Populatio
n 
Treatment Outc
ome 
meas
ure 
Treatment outcomes and Key Findings 
OncotypeDX 
Paik, 
et al. 
(2006)
(10) 
 
Prospectiv
e-
retrospecti
ve study in 
using 
existing 
trial data 
(NSABP B-
20).  
ER+, LN-, 
HER2+/- 
N=651/222
9 (28.9%) 
HT: 
tamoxifen 
(n=227) 
CHT: 
tamoxifen + 
CMF/MF 
(N=424). 
10-
year 
DRF
S 
Low RS: CHT = 4.4% / HT =3.2%; RR = 1.3 (0.46-3.78) 
Intermediate RS:  CHT = 10.9%/HT = 9.1%; RR=0.61 (0.24-
1.59) 
High RS:CHT = 11.9%/HT = 39.5%; RR = 0.26 (0.13-0.53) 
RS was correlated with chemotherapy benefit, (10-year 
DRFS). Significate benefit of chemotherapy in the high RS 
group (p = 0.001).  
Albain, 
et al. 
(2010)
(11) 
Prospectiv
e-
retrospecti
ve study 
from the 
SWOG-
8814 trial.   
ER+ 
and/or 
PR+,  
LN+  
(postmeno
pausal) 
N=367/927 
(39.6%) 
HT: 
tamoxifen 
(N=148) 
 
CHT: CAF 
>tamoxifen  
(N=219) 
10-
year 
DFS 
Low RS:  HR=1.02 (0.54-1.93) 
Intermediate RS: HR:0.72 (0.39-1.31) 
High RS: HR = 0.59 (0.35-1.01) 
10-
year 
OS 
Low RS:  HR=1.18 (0.55-2.54) 
Intermediate RS: HR:0.84 (0.40-1.78) 
High RS: HR = 0.56 (0.31-1.02) 
RS is prognostic for tamoxifen-treated patients with positive 
nodes and predicts significant benefit of CHT in tumours with 
a high recurrence score.   
Tang, 
et al. 
(2011)
(12) 
Prospectiv
e-
retrospecti
ve study 
from the 
NSABP-
B14 and 
B20 trial.    
ER+, LN-  
N=651 
(B20 
cohort) 
HT: 
tamoxifen 
 
CHT: 
tamoxifen + 
chemotherap
y 
 
 
DRFI P=0.031 for RS x treatment interaction 
 
OS  
 
P=0.011 for RS x treatment interaction 
 
DFS P=0.082 for RS x treatment interaction 
RS was significantly predictive of chemotherapy benefit. (for 
DRFI, for OS, and DFS), but for AoL was not.  In the larger B-
20 sub-cohort, AoL was significantly predictive of 
chemotherapy benefit for OS but not for DRFI or DFS.   
Tang, 
et al. 
(2010) 
(Abstr
act 
only)(1
3) 
Prospectiv
e-
retrospecti
ve study 
from the 
NSABP B-
20 trial.   
ER+, LN- 
N=625 
HT: 
tamoxifen 
CHT: NR 
DR HR=0.84 (P=0.037 for RS x treatment interaction). 
RS used alone remains the best predictor of chemotherapy 
benefit in ER+, N- breast cancer.   
Mammostrat 
Ross, Prospectiv ER+, LN- HT: DRFI Low risk:  improved by 5% from 86% to 91%, HR 0.4 (95%CI: 
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Autho
r 
(year) 
Design Populatio
n 
Treatment Outc
ome 
meas
ure 
Treatment outcomes and Key Findings 
et al. 
(2008)
(14) 
e-
retrospecti
ve study 
from the 
NSABP 
B14 and 
B20 trials 
 
N=711 
tamoxifen  0.2 ± 0.8),  
 
High risk: improved by 21% from 64% to 85%, HR 0.4 
(95%CI: 0.2 ± 0.9),  
 
Showing that these groups benefited from chemotherapy, 
whereas the patients in the intermediate risk group did not.   
RS = recurrence score, RR = Relative risk, HR = Hazard ratio, AoL = Adjuvant! Online, ER+ = oestrogen receptor positive, ER- = 
oestrogen receptor negative, LN- = lymph node negative, LN 1-3 = 1-3 lymph nodes involved, HT = hormone therapy, CHT = 
chemotherapy, CMF/MF, CAF = specific chemotherapy regimen, DRFS = Distant recurrence free survival, DRFI = Distant 
recurrence free interval, DFS = disease free survival, OS = Overall survival. 
Table 3:  Summary of patient characteristics, study characteristics, and key 
findings relating to changes in treatment recommendations  
Autho
r 
(year) 
Design Population Prior treatment 
recommendation 
Results 
OncotypeDX 
Oratz, 
et al., 
(2007)
(15) 
Retrosp
ective 
study 
N=74 Clinician treatment 
recommendation 
before and after 
GEP testing 
56 OHG WRFKDQJH LQ FOLQLFLDQV¶ WUHDWPHQW UHFRPPHQGDWLRQV
in 21% of patients, and in actual administered treatment in 
25% of patients. 
Asad, 
et al. 
(2008)
(16)  
Retrosp
ective 
chart 
review. 
ER+, LN- 
Mean age: 54 years 
N=85 
CHT for high risk 
based on 
international 
guidelines; and HT 
for low risk. 
RS led to changes in the decision for chemotherapy in 37 
(44%) of patients; 34% reduction in CHT recommendations.   
Rayha
nabad, 
et al. 
(2008)
(17) 
 
Retrosp
ective 
chart 
review. 
ER+, LN- 
Mean age: 54 years 
(range:26-78) 
N=58 
CHT for high risk 
based on 
international 
guidelines; and HT 
for low risk. 
RS led to change in management for 15 (26%) patients.   
Geffen
, et al. 
(2009)
(18) 
Prospec
tive 
study. 
LN- 
N=25 
Not reported RS led to a change in treatment recommendation for nine 
patients (36%).  Six (24%) from chemotherapy to no 
chemotherapy.    
Henry, 
et al. 
(2009)
(19) 
Retrosp
ective 
study. 
ER+, LN- 
N=29 
 
Medical oncologist 
opinion; clinical 
data, AoL risk 
estimates followed 
by RS. 
RS led to a change in CHT decisions in 9/29 (31%) patients, 
seven (24%) from CHT to no CHT and two (7%) from no 
CHT to CHT with low RS. 
 
Klang, 
et al. 
(2010)
(20) 
Retrosp
ective 
study 
N=313 Clinician treatment 
recommendation 
before and after 
GEP testing. 
RS led to change in treatment recommendations in 40% of 
patients; 27% reduction in CHT recommendations. 
Lo, et 
al. 
(2010)
Prospec
tive 
multicen
ER+, LN- 
Mean age: 55 years 
Clinician treatment 
recommendation 
before and after 
RS led to changes in clinician treatment recommendations 
for 28 patients (31.5%). 20 (22%)of  these were from CHT to 
HT.  Twenty-four patients (27%) changed their own 
29 
 
Autho
r 
(year) 
Design Population Prior treatment 
recommendation 
Results 
(21) tre study (range 35-77) 
N=89 
GEP testing. treatment decision, 9 from CHT to HT, 7 from HT to CHT, 2 
from undecided to HT, and 2 from undecided to CHT. 
Adem
uyiwa, 
et al. 
(2011) 
(22) 
Retrosp
ective, 
consecu
tive 
series. 
ER+,LN-, HER2- 
Mean age: 54.8 
years (range:29-82) 
N=276 
CHT 
recommendations 
based on 
clinicopathological 
characteristics 
RS led to change in treatment for 38% of patients with 37 
(13%) fewer patients receiving CHT. 
Geffen
, et al. 
(2011)
(23) 
Retrosp
ective 
study 
ER+ (N=134), LN-
/LN1 
Median age, 58 
range (33±75) 
N=135  
Treatment 
recommendations 
based on AoL. 
RS led to a change in treatment recommendation for 34 
(25.2%) patients.  This change was from CHT to no CHT for 
24 (17.8%) patients and from no CHT to CHT for 10 (7.4%). 
Joh, et 
al. 
(2011)
(24) 
Retrosp
ective 
study 
ER+ 
N=154 
Clinician panel RS led to a 25% change in treatment recommendations. 
 
Partin 
& 
Mamo
unas 
(2011)
(25) 
Retrosp
ective 
study 
ER+, LN- 
N=169 
Treatment 
recommendations 
based on AoL and 
St.Gallen 
RS led to change in treatment recommendation in 27-74% of 
patients depending on comparator guideline. 
Albane
ll, et 
al. 
(2012)
(26) 
Prospec
tive 
study 
ER+, LN-, HER2- 
Mean age: NR,  <50 
yrs (n=40), >50 yrs 
(n=67) 
N=107 
Treatment 
recommendation 
based on 
traditional 
clinicopathological 
factors. 
 
RS led to changes in treatment recommendations in 32% of 
107 patients enrolled: in 21% from CHT to HT and in 11% 
from HT to CHT. 
Bargall
o, et 
al. 
(2012)
(27) 
Prospec
tive 
study 
ER+, HER2-, LN-
/LN1-3 
Mean age: NR 
(range 32-89 years) 
N=96 
Treatment 
recommendation 
based on 
conventional 
clinical±
pathological 
factors and patient 
input. 
RS led to changes in treatment decisions for 31/96 (32%) 
patients, including 17/62 (27%) LN- patients and 14/34 
(41%) LN+ patients. The proportion of patients with a CHT 
recommendation decreased from 48% preǦ to 34% postǦ
assay. 
Birosc
hak, et 
al. 
(2013)
(28) 
Retrosp
ective 
study 
ER+, LN- 
Mean age: 60.2 
(range 39 to 78) 
N=50 
Treatment was 
recommended 
based on 
histologic 
assessment. 
RS led to changes in treatment decisions in 36 and 18% of 
cases by breast surgeons and medical oncologists, 
respectively.  Breast surgeons increased recommendations 
for CHT in 15 (30%) of cases and decreased to no CHT in 3 
(6%) of cases; and the medical oncologist increased to CHT 
in 4 (8%) of cases and decreased to no CHT in 5 (10%) of 
cases. 
Davids
on, et 
Prospec
tive 
ER+, HER2-, LN- 
Mean age: 53 
Treatment 
recommendation 
based on clinician 
RS led to changes in CHT recommendations in 45/150 
cases (30%) either to add (10%) or omit (20%) CHT.  
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Autho
r 
(year) 
Design Population Prior treatment 
recommendation 
Results 
al. 
(2013)
(29) 
study (range 23-78 years) 
N=150 
and patient pre-
assay 
questionnaires. 
De 
Boer, 
et al. 
(2013)
(30) 
Prospec
tive 
study 
ER+, HER2-, LN-
/LN1-3 
Mean age: 56.2  
N=151 
Treatment 
recommendation 
base on routine 
pathology. 
RS led to treatment recommendation changes for 24/101 
patients with LN- tumours (24%) and for 13/50 patients with 
LN+ tumours (26%). For patients with LN- tumours there was 
a change from CHT to HT for 23%, and for 25% of patients 
with LN+ tumours. 
Eierm
ann, et 
al. 
(2013) 
(31) 
Prospec
tive 
study. 
ER+, HER2-, LN-
/LN1 
Mean age: 56 
N=366 
Treatment was 
recommended 
based on available 
clinical and 
histopathological 
data. 
Treatment recommendations changed in 33% of patients. In 
25% of patients CHT was changed to no CHT. 
 
Holt, 
et al. 
(2013)
(32) 
Prospec
tive 
cohort 
ER+, LN-/LN1  
N=106  
Treatment 
recommendation 
base on NPI.  
35 patients (33%) had their initial recommendation changed 
as a result of RS whilst for 71 patients (67%) there was no 
change.  25 (23.5%) changed from CHT to no CHT.  
Cheun
g, et 
al. 
(2014)
(33) 
Retrosp
ective 
study 
ER+, HER2-, LN-
/LN1 
Mean age: 48 
(range 24-67 years) 
N=154 
Treatment 
recommendation 
based on clinical 
factors and AoL. 
RS led to a change in treatment recommendations for 20 
(31%) patients. 16 (10%) of these were changes to lower-
intensity regimens (either equipoise or HT). 
Fried, 
et al. 
(2014)
(34) 
Retrosp
ective 
study. 
ER+, LN-/+ 
(All intermediate 
RS) 
N=111 
Clinician treatment 
recommendation 
before and after 
GEP testing. 
RS led to a change in treatment recommendations for 24 
patients (21.6%).  Of 78 patients recommended HT alone, 
11 changed to CHT (14.1%); of 33 recommended CHT, 13 
received HT alone (39.4%). 
Jaafar, 
et al. 
(2014)
(35) 
Retrosp
ective 
study 
ER+, LN- 
N=47 
Treatment 
recommendation 
based on clinical 
factors. 
RS led to a treatment change for 13 patients (27.7%), and 
CHT use decreased overall, from 48.9 to 25.5%.  
Yama
uchi, 
et al. 
(2014)
(36) 
Prospec
tive 
study. 
ER+, LN-/LN1-3, 
HER2- 
N=124 
Treatment 
recommendations 
based on local and 
international 
guidelines. 
RS led to a change in treatment recommendations in 33% of 
node-negative (N0) and 65% of node-positive (ND) patients. 
In 27of 48 (56%) of N0 and 13 of 15 (87%) of N+ patients an 
initial recommendation for CHT was revised to HT after RS, 
and in 7 of 56 (13%) of N0 and 0 of 5 N+ patients from HT to 
CHT. 
Gligor
ov, et 
al. 
(2015)
(37) 
Prospec
tive 
study 
ER+, LN-/LN1, 
HER2- 
N=95 
Treatment 
recommendation 
based on clinical 
factors. 
RS led to changes in treatment recommendations in 37% of 
patients, predominantly from CHT to HT alone. Patients 
recommended CHT decreased from 52% to 25% post RS.  
Lee, et 
al. 
Retrosp
ective 
chart 
ER+, LN-/LN1 Treatment was 
recommended 
XVLQJLQVWLWXWLRQV¶
RS led to a change in treatment decisions in 115 of 212 
patients (54.2%), in 109 (51.4%) from CHT to HT, and in 6 
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Autho
r 
(year) 
Design Population Prior treatment 
recommendation 
Results 
(2015)
(38) 
review. N=212 guidelines, based 
on 
clinicopathologic 
characteristics. 
(2.8%) from HT to CHT. 
Zhang, 
et al. 
(2015)
(39) 
Prospec
tive 
study.  
 
ER+, LN- 
N=134 
Treatment 
recommendations 
based standard 
clinicopathologic 
criteria according 
to on St. Gallen 
and AoL. 
RS led to a change in treatment decisions for 29% of 
patients, with 6% (8/134) changing to receive CHT and 23% 
(31/134) changing to reject CHT. 
 
Kuchel
, et al. 
(2016)
(40) 
Prospec
tive 
study 
ER+, HER2-, LN-
/LN1-3 
N=135 
Clinician and 
patient 
recommendation 
before and after 
GEP testing. 
RS led to changes in clinician treatment recommendations in 
40.7% of patients. Of 69 patients with a pre-testing CHT 
recommendation, 43 (62.3%) had a recommendation change 
to HT only. Of the 66 patients with a pre-testing HT 
recommendation, 12 (18.2%) had a recommendation change 
to CHT. These changes led to a net reduction in the 
RQFRORJLVWV¶&+7UHFRPPendation rate from 50.4 to 27.7%. 
RS also led to 41 patients (31.3%) changing their treatment 
choice. Of the 52 patients with an initial CHT choice, 28 
patients (53.8%) changed their choice to HT only. Of the 79 
patients with an initial HT choice, 13 (16.5%) changed their 
choice to CHT. These changes led to a net reduction in CHT 
use from 39.7 to 28.2%. 
Levine
, et al. 
(2016)
(41) 
Prospec
tive 
study. 
ER+, LN-, HER2- 
N=979 
Treatment 
recommendations 
based on AoL. 
RS led to a change from unsure or CHT to no CHT in 365 
(38%), and changed from unsure or no CHT to CHT in 143 
(15%). CHT was recommended for 236 patients, 81% of 
whom received CHT.  
Ozme
n, et 
al. 
(2016)
(42) 
Prospec
tive 
study. 
ER+, LN-/LN1, 
HER2- 
N=165 
Treatment was 
recommended 
based on 
histologic 
assessment. 
RS led to a change in treatment decision for 33% of patients. 
Pre RS CHT was recommended to 92 (56%) of all patients, 
which decreased to 61 (37%) patients post-RS. 
MammaPrint 
Bueno
-de-
Mesqu
ita, et 
al. 
(2007)
(43); 
Drukk
er, et 
al. 
(2013) 
(44)  
Prospec
tive 
multicen
tre 
study. 
ER+/-, LN-/+ 
Mean age: 48 
N=427 
Treatment 
recommendations 
based on the 
Dutch Institute for 
Healthcare 
Improvement 
(CBO) guidelines. 
 
Guidelines in addition to the prognosis signature and patient 
preferences led to an actual change in treatment for 19% of 
patients.  2% more CHT, 5% more HT, and 6% more 
CHT+HT.  
At follow-XSSDWLHQWVZHUHFDWHJRUL]HGDV³ORZ-ULVN´E\
the 70-gene signature, but high-risk by other measures, such 
as age, tumor size, nodal status, and other 
clinicopathological factors. Of these, 76% did not receive 
chemotherapy, and 98% survived 5 years with no recurrence 
of disease. 
Geven
sleben
Consec
utive 
ER+/-, LN-/+ 
 
N=136 
Not reported.  GEP testing showed 40% of patients with either over (45%) - 
or undertreated (32%). 
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Autho
r 
(year) 
Design Population Prior treatment 
recommendation 
Results 
, et al. 
(2010)
(45) 
cohort  
Hartm
ann, et 
al. 
(2012) 
(46) 
Prospec
tive 
study. 
ER+, LN-/LN1, 
HER2- 
 
Mean age: 70.3. 
  
N=60 
 
Treatment 
according to 
national 
guidelines. 
The prognosis signature used in combination with the 
clinico-pathological factors, would have led to changes in 
18% of patients.  Recommendations for CHT for 6 additional 
patients (10%) and withheld in 5 patients (8%). 
Cusu
mano, 
et al 
(2014)
(47) 
Prospec
tive 
study. 
ER+/-, LN-/LN1-3,  
HER2+/- 
 
N=194 
Treatment 
recommendation 
based on 
clinicopathological 
factors. 
MammaPrint led to changes in treatment advice for 37% of 
patients by the Dutch (14% decrease in CHT), 24% by the 
Belgian (0% decrease in CHT), 28% by the Italian (13% 
increase in CHT) and 35% by the Spanish teams (2% 
decrease in CHT).  
 
MammaPrint increased the inter-institutional agreement in 
treatment advice (CHT or no CHT) from 51% to 75%. 
 
Drukk
er, et 
al. 
(2014)
(48) 
Retrosp
ective 
case 
review 
N=37 
 
(other factors not 
reported) 
Treatment 
recommendation 
based on 
clinicopathological 
factors. 
MammaPrint led to changes in treatment advice in 24% of 
cases.  Pre MammaPrint recommended treatments were 
CHT in 48%, and HT in 46% of the cases.  After adding 
MammaPrint recommended treatments were CHT 37%, and 
HT in 57% of cases.  
 
Adding MammaPrint resulted in 14.3% of the cases in a 
change from CHT to HT or no treatment.  In 2.1% of the 
cases the advice of no treatment or HT was changed to 
CHT. This resulted in a reduction in CHT use of 12.2%. 
Exner, 
et al. 
(2014)
(49) 
Prospec
tive 
study. 
ER+, LN-/LN1-3, 
HER- 
 
N=75 
Treatment 
according to 
clinicopathological 
factors and St 
Gallen guidelines. 
MammaPrint led to changes in treatment advice in 18.6% of 
cases. In 10 patients (13.3%), there was a decision change 
towards HT and in 4 patients (5.33%) towards CHT. 
IHC4  
Yeo, 
et al. 
(2015)
(50) 
Prospec
tive 
study 
ER+, LN-/LN1, 
HER2- 
 
Median age: 59 
 
N=124 
Treatment 
recommendation 
based on 
clinicpathological 
factors. 
IHC4 led to changes in treatment advice for 42 patients 
(34%).  Prior to the IHC4 score becoming available clinicians 
recommended CHT (or at least its discussion) to 74 (59%) 
patients, this fell to 32 (34%) after the IHC4 score. 
RS = recurrence score, AoL = Adjuvant! Online, NPI = Nottingham Prognostic Index,  ER+ = oestrogen receptor positive, ER- = 
oestrogen receptor negative, LN- = lymph node negative, LN 1-3 = 1-3 lymph nodes involved, HT = hormone therapy, CHT = 
chemotherapy. 
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Full-text articles and abstracts 
from previous reviews* 
(n = 11)  
S
cr
e
e
n
in
g
 
E
li
g
ib
il
it
y
 
Id
e
n
ti
fi
ca
ti
o
n
 
Records screened by title and abstract 
(n=7064) 
Full-text articles assessed for 
eligibility  
(n = 279) 
Full-text articles and abstracts 
excluded 
(n = 249) 
(Reasons for exclusion: 
Reviews, n = 64;  
Abstracts which did not add to the full published 
evidence base, n= 61;  
Pooled analysis, n= 4;  
Not a relevant test/research version of test, n= 
23;  
Reported in previous review (excluded here to 
avoid double counting), n = 8;  
Not relevant to the question e.g. case study, n= 
34;  
Unobtainable, n= 2 (both relating to 
OncotypeDX);  
Focussed on neoadjuvant setting, n= 3. 
Not relevant outcomes (e.g. Analytical validity or 
clinical validity) , n=50 
Excluded by title and abstract  
(n = 6785) 
Full text articles and 
abstracts (citations) included  
(n =30) 
In
cl
u
d
e
d
 
Studies included in narrative synthesis:  
x OncotypeDX- n= 32* 
x MammaPrint - n= 6*(7 citations) 
x IHC4 - n= 1 
x Mammostrat - n=1 
 
*Includes citations identified from the searches of previously reported 
systematic reviews.  
Records identified through 
database searching  
(n =7059) 
Additional records identified 
through other sources  
(n = 5) 
Figure 1:  PRISMA Diagram 
 
 
 
 
  
 
 
